Ken Rekowski, Shawn Hill and Jodi Graham are dealing with COVID-19 in different ways

You’re working on some text in Photoshop for your photo. Things are going along great…until you realize that your text is horribly pixelated! Why? You may have even created this exact type of file before and not had this problem. Why is the text pixelated now? There are a few things that can cause pixelated text in Photoshop. The good Continue Reading

The post 6 Causes of Pixelated Text in Photoshop and Their Fixes appeared first on Photodoto.

Photography Life has just contributed to the selection of online courses that you can take for free. While their premim courses are normally paid $150 per course, you can now access them free of charge. The founders have released them on YouTube, available for everyone to watch. The Photography Life team came to the decision […]

The post Photography Life makes all their paid premium courses free appeared first on DIY Photography.

Have you noticed extra-long and weirdly stretched images on your Instagram feed? It looks like some kind of a glitch has appeared, allowing users to post images like this to their followers. Of course, some Instagrammers have made the use of it to draw attention, and if you want to have some fun (or annoy […]

The post Weird glitch lets you post insanely long photos to Instagram appeared first on DIY Photography.

It feels like forever since Nikon announced their newest flagship DSLR; the Nikon D6. It’s actually only been three months, but that hasn’t stopped some people getting anxious. Recently, customers were being told that the D6 would start shipping right about now, but now Nikon has officially come out to announce that the Nikon D6 […]

The post Nikon has confirmed that their flagship D6 DSLR will start shipping on May 21st appeared first on DIY Photography.

We derive the non-relativistic $c oinfty$ and ultra-relativistic $c o 0$ limits of the $kappa$-deformed symmetries and corresponding spacetime in (3+1) dimensions, with and without a cosmological constant. We apply the theory of Lie bialgebra contractions to the Poisson version of the $kappa$-(A)dS quantum algebra, and quantize the resulting contracted Poisson-Hopf algebras, thus giving rise to the $kappa$-deformation of the Newtonian (Newton-Hooke and Galilei) and Carrollian (Para-Poincar'e, Para-Euclidean and Carroll) quantum symmetries, including their deformed quadratic Casimir operators. The corresponding $kappa$-Newtonian and $kappa$-Carrollian noncommutative spacetimes are also obtained as the non-relativistic and ultra-relativistic limits of the $kappa$-(A)dS noncommutative spacetime. These constructions allow us to analyze the non-trivial interplay between the quantum deformation parameter $kappa$, the curvature parameter $eta$ and the speed of light parameter $c$.

We study a class of fourth order nonlinear parabolic equations which include the thin-film equation and the quantum drift-diffusion model as special cases. We investigate these equations by first developing functional inequalities of the type $ int_Omega u^{2gamma-alpha-eta}Delta u^alphaDelta u^eta dx geq cint_Omega|Delta u^gamma |^2dx $, which seem to be of interest on their own right.

Let $X$ (resp. $Y$) be a curve of genus 1 (resp. 2) over a base field $k$ whose characteristic does not equal 2. We give criteria for the existence of a curve $Z$ over $k$ whose Jacobian is up to twist (2,2,2)-isogenous to the products of the Jacobians of $X$ and $Y$. Moreover, we give algorithms to construct the curve $Z$ once equations for $X$ and $Y$ are given. The first of these involves the use of hyperplane sections of the Kummer variety of $Y$ whose desingularization is isomorphic to $X$, whereas the second is based on interpolation methods involving numerical results over $mathbb{C}$ that are proved to be correct over general fields a posteriori. As an application, we find a twist of a Jacobian over $mathbb{Q}$ that admits a rational 70-torsion point.

A reaction-diffusion model was developed describing the spread of the COVID-19 virus considering the mean daily movement of susceptible, exposed and asymptomatic individuals. The model was calibrated using data on the confirmed infection and death from France as well as their initial spatial distribution. First, the system of partial differential equations is studied, then the basic reproduction number, R0 is derived. Second, numerical simulations, based on a combination of level-set and finite differences, shown the spatial spread of COVID-19 from March 16 to June 16. Finally, scenarios of unlockdown are compared according to variation of distancing, or partially spatial lockdown.

Calling all fearless freaks! Mark your calendars: The Flaming Lips have rescheduled their now-canceled April gig at the Fox Theater for March 19, 2021.…

In times of trouble, escaping into the art that calms you is key to keeping your sanity.…

The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionizing radiation.

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

The invention relates 6-acyl-(6H)-dibenz[c,e][1,2]oxaphosphorin-6-oxides of the formula ##STR1## wherein each of R1, R2 and R3 may be present one or more times and R1, R2 and R3 represent halogen having an atomic number of from 9 to 35, alkyl or alkoxy each having from 1 to 6 carbon atoms and wherein Ar represents an aromatic hydrocarbon group having from 6 to 10 carbon atoms.The invention further relates to a process for the preparation of the afore-mentioned compounds and polymerizable compositions containing them as an essential ingredient as a photo-initiator. Finally the invention relates to 6-alkoxy-(6H)-dibenz[c,e][1,2]oxaphosphorin of the formula II ##STR2## wherein each of R1 and R2 may be present once or more times and R1 and R2 represent halogen having an atomic number of from 9 to 35, alkyl or alkoxy each having from 1 to 6 carbon atoms, at least one R1 being, however, halogen and wherein R4 represents alkyl having from 1 to 6 carbon atoms.

Compounds of formula (I) ##STR1## in which R1 is hydrogen, O°, CN, NO, cyanomethyl, C1 -C12 -alkyl, C3 -C12 -alkenyl or C3 -C12 -alkynyl subject to the proviso that the carbon atom attached to the nitrogen atom is a primary carbon atom, C7 -C12 -aralkyl, C1 -C12 -acyl, 2,3-epoxypropyl, OH-monosubstituted C2 -C6 -alkyl or 2,3-dihydroxypropyl, R2 is hydrogen, C1 -C18 -alkyl, C5 -C18 -cycloalkyl, C6 -C18 -aryl or C7 -C18 -aryalkyl, R3 is C6 -C18 -aryl or a group of the formula (II) ##STR2## in which R1 is as defined above, n is an integer from 1 to 4 and R4 is an organic or inorganic radical of a valency equal to n are useful for stabilizing organic material against oxidative, thermal and/or light induced degradation.

Antivirally active compounds of formula (I), wherein R1 is hydrogen, hydroxy, mercapto or amino; R2 is hydrogen, hydroxy, fluoro, chloro or amino; R3 and R4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R3 together with R4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R2 is amino and R3 and R4 are hydroxy, R1 is not hydroxy and in addition, when n=1, R1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS. ##STR1##

The preparation of phosphorescent metalloporphyrin labelling reagents and their use for preparation of phosphorescent conjugates with biomolecules. The labelling reagents obtainable are water soluble monofunctional derivatives of Pt- and Pd-coproporphyrins, where the term “monofunctional” refers to the number of reactive groups in the porphyrin moiety.

Disclosed herein are acrylic and methacrylic acid ester-based polymeric materials containing as flexibilizing and brittleness reducing agents 1-60% of C4-C8 polyalkylene or polyalkyldiene compounds, preferably having a molecular weight of 300-2100, and the use of such materials in dentistry and medicine.

Fluorinated aromatic materials, their synthesis and their use in optoelectronics. In some cases, the fluorinated aromatic materials are perfluoroalkylated aromatic materials that may include perfluoropolyether substituents.

This invention provides a method related to the preparation of derivatives of poly(ethylene glycol), wherein the method comprises increasing the pH of an aqueous composition comprising a poly(ethylene glycol) bearing a —O—(CH2)n—CO2R3 functional group to result in an aqueous composition comprising a poly(ethylene glycol) bearing a —O—(CH2)n—CO2H functional group, wherein R3 is alkyl and (n) in each instance is 1-6.

The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a method for application of malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and which can be encountered in the air, on textiles, bathroom or kitchen surfaces, and the like. The composition may be applied as is or in the form of a perfuming composition or in a consumer product or article containing the compound or perfume composition.

A microcapsule comprising A) a core containing a hydrophobic liquid or wax, B) a polymeric shell comprising a) a polymer formed from a monomer mixture containing: i) 1 to 95% by weight of a hydrophobic mono functional ethylenically unsaturated monomer, ii) 5 to 99% by weight of a polyfunctional ethylenically unsaturated monomer, and iii) 0 to 60% by weight of other mono functional monomer, and b) a further hydrophobic polymer which is insoluble in the hydrophobic liquid or wax. The invention includes a process for the manufacture of particles and the use of particles in articles, such as fabrics, and coating compositions, especially for textiles.

The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula: wherein m and n are integers of 0 or 1, with the proviso that when m is 0, n is 1 and when m is 1, n is 0; andwherein the dashed circle represents either single or double bonds.

A para-methoxy protected benzaldehyde useful in preparation of treprostinil, and of formula: (Formula (1)) is prepared by subjecting to Claisen re-arrangement a substituted benzaldehyde of formula (1a): (Formula (Ia)) to form the m-hydroxy-substituted benzaldehyde of formula (1b): (Formula (Ib)) and then reacting compound (1b) with a p-methoxybenzyl (PMB) compound to form a PMB-substituted benzaldehyde of formula (1).

A polyether polyol based on renewable materials is obtained by the in situ production of a polyether from a hydroxyl group-containing vegetable oil, at least one alkylene oxide and a low molecular weight polyol having at least 2 hydroxyl groups. The polyol is produced by introducing the hydroxyl group-containing vegetable oil, a catalyst and an alkylene oxide to a reactor and initiating the alkoxylation reaction. After the alkoxylation reaction has begun but before the reaction has been 20% completed, the low molecular weight polyol having at least 2 hydroxyl groups is continuously introduced into the reactor. After the in situ made polyether polyol product having the desired molecular weight has been formed, the in situ made polyether polyol is removed from the reactor. These polyether polyols are particularly suitable for the production of flexible polyurethane foams.

A superconducting structure (1) has a plurality of coated conductor tapes (2; 2a-2o), each with a substrate (3) which is one-sided coated with a superconducting film (4), in particular an YBCO film, wherein the superconducting structure (1) provides a superconducting current path along an extension direction (z) of the superconducting structure (1), wherein the coated conductor tapes (2; 2a-2o) provide electrically parallel partial superconducting current paths in the extension direction (z) of the superconducting structure (1), is characterized in that the coated conductor tapes (2; 2a-2o) are superconductively connected among themselves along the extension direction (z) continuously or intermittently. A more stable superconducting structure with which high electric current strengths may be transported is thereby provided.

Alkyl nitrate ester compounds are provided for the delivery of nitric oxide to targeted muscle tissues, and in particular, to normal and dystrophic muscles. In one aspect, nitrate ester compounds are provided having the following formula: wherein, R1 is ONO2, CH2ONO2, CnH2n+1OH, CnH2n+1OH, or CH2CH2CH3, or H;R2 is ONO2, CH2ONO2, Cn'H2n'+1OH, Cn'H2n'+1OH, CH2CH2CH3 or H; andR3 is ONO2, CH2ONO2, Cn'″H2n″+1OH, Cn″H2n″+1OH, CH2CH2CH3 or H; wherein n is an integer from 0 to 9, n' is an integer from 0 to 9, and n″ is an integer from 0 to 9, and n+n'+n″≦9, and wherein at least one of R1, R2, and R3 is an ester nitrate selected from the group consisting of ONO2, CH2ONO2, and combinations thereof.

The esterfication of hypophosphorous acid is followed by reaction with another molecule of alcohol under the action of a nickel catalyst to provide a green method for the preparation of H-phosphonate diesters. This method avoids the need for any stoichiometric chlorine unlike those based on phosphorous trichloride.

The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.

The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis.

The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.

Disclosed are novel ruthenium compounds of formula (Ia) and (Ib): wherein R1 and the moiety are defined herein. Also disclosed is a process for using these novel ruthenium compounds as catalysts for asymmetric hydrogenation and transfer hydrogenation of ketones with high reactivities and excellent selectivities.

Compounds of the formula where R1 each individually is identical or different and is a hydrocarbon radical, R2 each individually is hydrogen or a methyl radical, n is an integer from 6 to 11, and m is 0 or 1, with the proviso that the sum of the number of carbon atoms in the three radicals R1 in the compound of the formula (I) is 6 to 24, can be admixed with curable polymer compositions to form products with hydrophilic surfaces, or can be applied to surfaces to render them hydrophilic.

Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.

The invention provides a method for synthesizing 7-Acetyleno quinone methide compounds that is safe and inexpensive. The method avoids the need for extremely cold reaction temperatures and unlike the prior art does not require any highly explosive materials. The method comprises the steps of: a) performing a condensation reaction between 3,5-di-tert-butyl-4-hydroxybenzaldehyde and a secondary amine thereby forming a secondary amine quinone methide intermediate;b) removing water from the secondary amine quinone methide intermediate by azeotropic distillation;c) adding the dehydrated secondary amine quinone methide intermediate to an organic medium containing a metal acetylide to form a Mannich base intermediate; andd) adding a release agent to the Mannich base intermediate to yield a 7-Acetyleno quinone methide.

This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.

This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 and (20R)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.

A centrifuge, including: a flange closing off one axial end of a separation chamber; a plurality of apertures that traverse axially through the flange at a radial distance from a flange axis, wherein at least one aperture is in fluid communication with a first outlet passage; a plurality of weir inserts removably disposed within the plurality of apertures to control a flow of one or more fluids from the separation chamber; wherein at least one weir insert disposed within the at least one aperture in fluid communication with the first outlet passage is changeable to prevent or allow fluid communication between the separation chamber and the first outlet passage.

Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Disclosed are two-component lignosulfonate adhesives, methods of synthesizing two-component lignosulfonate adhesives, kits comprising two-component lignosulfonate adhesives and methods of using two-component lignosulfonate adhesives.

Adhesive copolymers and methods for preparing them are disclosed. An adhesive copolymer may be prepared from a reaction mixture containing monosaccharide monomers and dicarboxylic monomers. The monosaccharide monomers may include any of a number of C5 and/or C6 monosaccharides.

Black disazo dyes of general formula (V) wherein A is a moiety of formula (VI) or of formula (VII) and B is a moiety of formula (VII) or of formula (IX) and wherein M, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, and R24, are as defined in the specification, are excellent black dyes for dying and printing cellulose containing materials and textile materials and, in particular, for preparation of recording liquids for ink jet printing and for writing utensils.

The invention relates to the use of NF-κB inducing kinase (NIK) and related molecules for the modulation of signal activities controlled by cytokines, and some new such molecules.

Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop 4 (residues 92-97) of NGF, respectively, displaying nerve growth factor (NGF) agonist or partial agonist activity.

A fullerene derivative, with a solubility in n-hexane of not lower that 0.1 mg/ml at 25° C., includes a fullerene skeleton and three or more organic groups attached to the fullerene skeleton, where each of the organic groups is represented by the general formula (III): —CH2—X (R2)(R3)(R4) (III) where X represents an element belonging to the group 14 in the periodic table; and R2, R3 and R4 may be the same or different and each represents a hydrogen atom, hydrocarbon group, alkoxy group or amino group.

The novel metallocenes of the formula I in which, preferably, M1 is Zr or Hf, R1 and R2 are alkyl or halogen, R3 and R4 are hydrogen, R5 and R6 are alkyl or haloalkyl, —(CR8R9)m—R7—(CR8R9)n— is a single- or multi-membered chain in which R7 may also be a (substituted) hetero atom, m+n is zero or 1, and R10 is hydrogen, form, together with aluminoxanes as cocatalysts, a very effective catalyst system for the preparation of polyolefins of high stereospecificity and high melting point.

Sliding element for seals includes 25 to 75 weight % carbonaceous impalpable powdery aggregate of non-graphitizing carbon and/or graphitizing carbon and 20 to 50 weight % synthetic resin as binder. The sliding element is blended with the range of 5 to 25 weight % carbonaceous carbon fibers without surface treatment and inside the carbon matrix, the carbon fibers are randomly scattered.

A process is described for preparing aryllithium compounds by reaction of metallic lithium in an ether-containing solvent with an aryl halide, wherein prior to or at the beginning of the reaction a catalyst is added, the catalyst containing a halogen-free, polynuclear aromatic (aryl catalyst) or consisting of such a compound.

The present invention relates to a process of synthesis of α-sialyl oligosaccharides and in particular of 6'-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.